13 results about "STREPTOCOCCUS ANTIGEN" patented technology

The invention relates to a group B streptococcus oligoglycoprotein conjugate as well as a preparation method and application thereof, and belongs to the technical field of group B streptococcus vaccine development. Inactivated group A streptococcus C5a peptidase ScpA193 is used as a carrier and is connected with group B streptococcus oligosaccharide antigens to prepare the group B streptococcus-resistant oligosaccharide protein conjugate, and the oligosaccharide antigens are oligosaccharide trisaccharide derivatives, oligosaccharide pentasaccharide derivatives or oligosaccharide octasaccharide derivatives of group B streptococcus cell wall surface polysaccharides. The oligosaccharide protein conjugate prepared by the invention can simultaneously induce two types of antibodies with different target spots to synergistically aim at group B streptococcus, and is a compound vaccine. The vaccine has better applicability, can more effectively inhibit group B streptococcus, and is not limited by the problem of bacterial drug resistance caused by use of a large amount of antibiotics.

The application discloses a HtsA-SLOdm fusion protein and application thereof in preparation of a group A streptococcus vaccine. The HtsA-SLOdm fusion protein is obtained by fusing and recombining a heme transport lipoprotein (HtsA) and a streptolysin protein containing a double-mutation site (SLOdm), can induce production of HtsA protein and SLOdm protein specific IgG antibodies in serum, has strong immunogenicity, can induce high-level IgG1 and IgG2a antibody titers, and the humoral immune response in inducing production of SLOdm protein specific IgG antibodies in serum is stronger than that of a single protein. In addition, the HtsA-SLOdm fusion protein can promote skin wound healing of mice, reduce bacterial content and inflammatory response at a skin infection site of the mice, accelerate wound healing, has almost no hemolytic activity, has high safety, and can be used for preparing a group A streptococcus vaccine.

The invention discloses a primer probe composition and a kit for group A streptococcus species identification and M1UK and M1global subtype typing and application of the primer probe composition and the kit. According to the primer probe composition, quadruple target amplification primers and probes are designed, so that specific amplification can be achieved in a single tube, and cross interference is avoided; the primer probe group forms a species-type-double SNP subtype three-stage detection system and is used for preparing detection kits for GAS species identification, em1 type confirmation, M1UK / M1global subtype typing and the like, interference of other em1 derived sublines is eliminated according to the double SNP co-occurrence requirement, and the M1UK typing accuracy is remarkably improved. The kit has the advantages of high specificity, high throughput, simplicity and convenience in operation and low cost, and is suitable for clinical diagnosis, high-virulence clone screening and public health emergency monitoring.

The invention discloses a group A streptococcus mRNA (messenger Ribonucleic Acid) vaccine and application thereof, and relates to the technical field of biological medicines, in particular to the group A streptococcus mRNA vaccine and application thereof. The mRNA for coding the group A streptococcus antigen contains an open reading frame; the nucleotide sequence of the coding open reading frame is M12 <-N > + M1 <-N > + M4 <-N >, and is as shown in SEQ ID NO. 1; the antigen sequence of the group A streptococcus mRNA vaccine has no homology with human tissue protein through blastp comparison; the mRNA vaccine has strong immunogenicity, can effectively inhibit three GAS serotypes, and covers main GAS epidemic strains in China at present; the mRNA vaccine has the advantages of high efficiency, broad spectrum, high safety and simplicity and convenience in use, and is easy to popularize and use.

A composition comprising isolated Streptococcus pyogenes extracellular vesicles (EVs) suspended in a vehicle, for use in eliciting an adaptive immune response against group A streptococcus (GAS) in a subject. The EVs may comprise antigens MtsA, Spy_1228, PrsA1, PrsA2, SPy_0319 and / or GlnP. A composition comprising isolated S. pyogenes protein(s) MtsA, SPy_1228, PrsA1, PrsA2, GlnP, SPy_0319 and / or MalX. The compositions may be used for inducing protective immunity in a subject against a GAS infection, such as streptococcal pharyngitis, scarlet fever, impetigo, streptococcal meningitis, streptococcal sinusitis, necrotizing fasciitis, cellulitis, streptococcal toxic shock syndrome, rheumatic fever and post-streptococcal glomerulonephritis.

A composition comprising isolated Streptococcus pyogenes extracellular vesicles (EVs) suspended in a vehicle, for use in eliciting an adaptive immune response against group A streptococcus (GAS) in a subject. The EVs may comprise antigens MtsA, Spy_1228, PrsA1, PrsA2, SPy_0319 and / or GlnP. A composition comprising isolated S. pyogenes protein(s) MtsA, SPy_1228, PrsA1, PrsA2, GlnP, SPy_0319 and / or MalX. The compositions may be used for inducing protective immunity in a subject against a GAS infection, such as streptococcal pharyngitis, scarlet fever, impetigo, streptococcal meningitis, streptococcal sinusitis, necrotizing fasciitis, cellulitis, streptococcal toxic shock syndrome, rheumatic fever and post-streptococcal glomerulonephritis.

Provided herein are methods of immunizing against, treating or preventing streptococcal toxic shock syndrome in a subject, by administration of a group A streptococcus M protein, inclusive of fragments, variants or derivatives thereof, or an antibody that binds, or is raised against the M protein and optionally a group A streptococcus superantigen protein, inclusive of fragments, variants or derivatives thereof, or an antibody or antibody fragment that binds, or is raised against, the superantigen protein.

The invention provides a group B streptococcus antigen detection kit, which belongs to the technical field of antigen detection, and comprises the following components: a reagent card, an ID card, an extraction liquid and an extraction tube, the reagent card comprises a reagent strip, a light-transmitting film and a card shell; the reagent strip comprises a sample pad, a combination pad, a nitrocellulose membrane, an absorption pad and a PVC (Polyvinyl Chloride) bottom plate; the combination pad contains a group B streptococcus antibody a marked by latex microspheres and chicken IgY marked by fluorescent microspheres; the nitrocellulose membrane contains a group B streptococcus antibody b and a goat anti-chicken IgY polyclonal antibody. According to the technical scheme provided by the invention, the antibody with high sensitivity and strong specificity is prepared, and meanwhile, the false positive interpretation is reduced.

The application provides a group B streptococcus antigen detection kit, and belongs to the technical field of antigen detection, and comprises the following components: a reagent card, an ID card, an extraction solution and an extraction tube; the reagent card comprises a reagent strip, a light transmission film and a card shell; the reagent strip comprises a sample pad, a binding pad, a nitrocellulose film, an absorption pad and a PVC bottom plate; the binding pad contains latex microsphere-labeled group B streptococcus antibody a and fluorescent microsphere-labeled chicken IgY; and the nitrocellulose film contains group B streptococcus antibody b and goat anti-chicken IgY polyclonal antibody. The technical scheme provided by the application realizes preparation of an antibody with high sensitivity and strong specificity while reducing false positive judgment.

The invention provides a novel streptococcus group A oligosaccharide antigen and glycobinding protein vaccine, which is characterized in that oligosaccharide antigen containing 30-70% of N-acetyl glucamine multi-rhamnose core skeleton structure is accurately prepared through chemical synthesis, and is efficiently coupled with KLH (the loading capacity is about 215 oligosaccharide / KLH molecules); safe, efficient and broad-spectrum immune protection is realized; safety: the GlcNAc side chain modification design avoids autoimmune risks (such as acute rheumatic fever heat); high efficiency: the animal experiment antibody titer reaches 1: 12, 800; the broad spectrum is as follows: the highly conservative universal GAS oligosaccharide antigen can universally cover various serotypes, and the key synthetic route (Scheme 2, 3, 16 and 20, the yield is 22%-96%) and the loading capacity verification (HPAEC) support the technical feasibility.

The present disclosure relates to the field of vaccines to protect against disease caused by group A streptococcus (GAS) bacteria, and methods of using the same. In particular, the present disclosure relates to immunogenic compositions comprising a J8 peptide and a p*17 peptide.

The present disclosure generally relates to autoimmune diseases, disorders and conditions associated with a Group A Streptococcus infections and methods of treating or preventing such diseases, disorders or conditions, or more particularly rheumatic fever, rheumatic heart disease and Sydenham's chorea.